HIV remains one of the most serious challenges to world health, particularly in sub-Saharan Africa, where the national adult prevalence in eight countries currently exceeds 15%. During 2007, 1.9 million people were newly infected with the virus, and approximately half of those were young people under the age of 25 years (35, 36) .
Since their introduction in the 1980s, immunoassay-based serological tests for HIV have enabled the simple rapid detection of infection and have been widely implemented as screening tools for both diagnosis and epidemiological monitoring. Concerns about the specificity of serological tests for HIV when sera from sub-Saharan Africa were tested were first raised in the 1980s. False-positive reactions in enzyme immunoassays (EIAs) that used viral lysate antigens were attributed to polyclonal B-cell activation as a result of malaria and other endemic infections (3-5, 7, 16, 19, 26, 33) . The reduced specificity was addressed in part by the use of recombinant proteins and synthetic peptides instead of human viral lysates in later-generation EIAs.
Pressure to detect early HIV infections has resulted in the development of EIAs of enhanced sensitivity. Several published studies have suggested that these 4th-generation assays, which by definition detect both HIV antigen and HIV antibody, are both highly sensitive and specific (1, 6, 25) . However, we have previously reported a lack of specificity in one of those assays, the Murex HIV Ag/Ab Combination EIA (13) . In a study of over 7,000 adolescents and young adults in northwestern Tanzania, the assay had a specificity of 91.5% and a positive predictive value of only 7.9%. We describe here the clinical and biological factors associated with the false positivity of that assay. We believe that this is the first report to identify the immunological factors associated with false-positive HIV test results in an adolescent and young adult population in subSaharan Africa.
MATERIALS AND METHODS
Study population and study design. A community-randomized trial of a multicomponent sexual health intervention (MEMA kwa Vijana [MkV]) was conducted among young people in 20 distinct communities within the Lake Victoria region of Tanzania between 1999 and 2002. The design and the results of the trial have been reported previously (18, 31) . At the follow-up survey in 2002, serum samples from 7,333 individuals aged 16 to 27 years were tested for HIV infection by using the Murex HIV Ag/Ab Combination EIA (Murex Biotech, Dartford, Kent, United Kingdom). The participants were interviewed about their sexual behavior and underwent clinical assessment by use of a syndromic approach for signs and symptoms of sexually transmitted infections (STIs). Serum samples were tested for lifetime exposure to Treponema pallidum (syphilis) and herpes simplex virus type 2 (HSV-2) antibodies. In addition, the participants were tested for possible Schistosoma haematobium exposure by using a red blood cell (RBC) urine dipstick test (Becton Dickinson, Oxford, United Kingdom) and treated according to Tanzanian guidelines. An RBC dipstick result of 3ϩ or 4ϩ was presumed to be a positive result for Schistosoma haematobium in all participants except female participants who were menstruating. In those cases, the participant was treated for schistosomiasis if she reported noticing blood in her urine when she was not menstruating. Pregnant females who were diagnosed with possible schistosomiasis were referred to the nearest health center for treatment after delivery. The participants were treated syndromically for malaria if they presented with fever.
In the cohort of 7,333 individuals, 674 (9.2%) serum samples were initially reactive by the Murex EIA, according to the manufacturer's criteria; however, only 53 were found to be HIV positive on confirmatory testing (13) , giving an overall HIV prevalence of 0.7%. Although females were more likely than males to be confirmed to be HIV positive (1.5% of females versus 0.2% of males), similar proportions of males (8.1%) and females (8.4%) had false-positive results. To investigate the factors associated with the high proportion of false-positive results, a random collection of 240 and 284 Murex EIA-negative sera, sampled to provide an equal number of males and females, was taken for immunological analysis. Negative sera were selected from a subgroup that had been tested by an additional HIV assay for a separate validation study, which included all samples that were positive for syphilis. Sera, which had been frozen at Ϫ20°C, were transported to the Department of Pathology, University of Cambridge, Cambridge, United Kingdom, and tested for IgG antibodies to malaria and schistosoma parasites, heterophile antibody, and rheumatoid factor (RF) titer.
Laboratory methods. Sera were tested for HIV-1 and HIV-2 by the Murex HIV Ag/Ab Combination EIA; reactive specimens were sent to the United Kingdom Central Public Health Laboratory for confirmation of the results. Full details of the HIV testing algorithm and confirmatory testing have been described previously (13) ; but in brief, three further EIAs, a p24 antigen test, an in-house PCR with pol-specific primers, and a Western blot assay, were used as part of the Central Public Health Laboratory confirmatory algorithm. A specimen was defined as false positive if it did not contain HIV-1 RNA.
IgG isotype analysis was performed by in-house enzyme-linked immunosorbent assays to determine the levels of IgG isotypes 1 to 4 to S. mansoni soluble worm and egg antigens, S. haematobium soluble worm antigen, and Plasmodium falciparum antigen. S. haematobium soluble egg antigen was unavailable at the time of testing. An in-house test was also performed to determine the presence of heterophile antibody. The details of the IgG assays have been described previously (14, 28) . S. mansoni antigens were obtained from a Puerto Rican isolate of S. mansoni maintained in the outbred Tucks original strain of mice (Harlan United Kingdom Ltd., Bicester, United Kingdom) and albino freshwater snails (Biomphalaria glabrata) in Cambridge (11) . S. haematobium soluble worm antigen and P. falciparum crude schizont extract were supplied by collaborating laboratories of the Department of Pathology, University of Cambridge.
The RF titer was measured by the agglutination method with a Waaler Rose rheumatoid factor kit (bioMérieux, Basingstoke, United Kingdom). Lifetime exposure to syphilis was examined by using a Treponema pallidum particle agglutination (TPPA) test (Serodia TPPA test; Fujirebio Inc., Tokyo, Japan). Sera were tested for antibodies to HSV-2 by using a monoclonal enzyme immunoassay (HSV-2 IgG; Kalon Biological Ltd., Ash Vale, United Kingdom).
Statistical analyses. Data were double-entered into and verified by use of the Dbase-IV program and analyzed by using Stata (version 10.0) software (Stata Corporation, College Station, TX). First, logistic regression was used to examine univariate associations of sociodemographic and clinical factors with false-positive Murex EIA results for HIV-negative members of the cohort. The analysis was restricted to individuals for whom complete sociodemographic and clinical data were available. Second, since the prevalence of schistosomiasis and other infections was likely to differ among the 20 communities involved in the trial, conditional logistic regression was used to examine the association with each factor, controlling for community. All factors whose adjusted univariate association with false positivity reached significance at a P value of Ͻ0.10 were included in a multivariate model; factors that remained independently associated with the outcome at a P value of Ͻ0.05 were retained.
Next, immunological factors (IgG antibodies to malaria and schistosomiasis, heterophile antibody, and rheumatoid factor titer) associated with false-positive Murex EIA results were analyzed for a subsample of 524 HIV-negative serum samples by using conditional logistic regression. The analysis was conditioned on community. Since females and those with TPPA test-positive results were oversampled among the Murex EIA-negative controls, the analysis was adjusted for sex, age, and TPPA test results. For each antibody test, the results were converted from continuous optical density (OD) values into an ordered, four-category variable for analysis, based on the quartiles of the OD distribution for the samples Murex EIA-negative results.
Immunological variables that had a significant linear association with false positivity (P-value trend Ͻ 0.05), adjusted for age, sex, TPPA test result, and community, were considered for inclusion in a multivariate model. Many of the antibody tests were colinear, so the multivariate model was built in two stages. First, immunological variables that had a positive linear association with false positivity by the Murex EIA were added to the model, one at a time, in order of decreasing strength of association in the univariate analysis. Variables that improved the model fit by a P value of Ͻ0.10 by use of the likelihood ratio test were retained. Second, immunological variables that were inversely associated with false positivity were added to the multivariate model, one at a time, by using the same approach. Lastly, the final model was reached by excluding variables one at a time until all remaining immunological variables were significant at the level of a P value of Ͻ0.05.
Ethical approval. Ethical clearance for the main study was obtained from the Tanzanian Medical Research Coordinating Committee and the Ethics Committee of the London School of Hygiene and Tropical Medicine.
RESULTS
Of 7,280 HIV-negative participants, complete questionnaire and clinical data were available for 6,940 (95.3%), and those data were included in the analysis of sociodemographic and clinical risk factors (6,366 Murex EIA-negative participants and 574 participants with false-positive Murex EIA results; Table 1 ). The mean (standard deviation [SD]) age was 18.1 (1.3) years; 58.5% of the participants were males.
In the univariate analysis, the sociodemographic factors associated with false-positive results included ethnic group, being unemployed, and marital status (although that factor had less of an association among those who were previously married). However, after controlling for community, none of the sociodemographic factors was significantly associated with falsepositive results. In the univariate analysis of clinical symptoms, a diagnosis of possible schistosomiasis and higher scores by the urine RBC dipstick test were significantly associated with false positivity. False-positive results were less prevalent in participants with respiratory tract infections. Those associations remained after community was controlled for. In the multivariate model, a diagnosis of possible schistosomiasis was an independent risk factor for false-positive results (adjusted odds ratio [OR] ϭ 1.37, 95% confidence interval [CI] ϭ 1.11 to 1.70). In addition, false-positive results were inversely associated with respiratory tract infection (adjusted OR ϭ 0.56, 95% CI ϭ 0.31 to 1.00). There was no significant association between a diagnosis of malaria and a false-positive result or between HSV-2 or TPPA serology and false-positive results in either the univariate or the adjusted analysis.
A subsample of 524 HIV-negative participants (284 Murex EIA negative and 240 Murex EIA false positive; Table 2) were included in the analysis of the immunological factors associated with false-positive results; their mean (SD) age was 18.0 (1.3) years, and 50.0% were males. In the univariate analysis, false-positive results were significantly associated with increasing levels of S. mansoni egg IgG1 and IgG3, increasing S. haematobium worm IgG1, and an RF titer of Ն80 (Table 2 ). In addition, false-positive results were significantly associated with decreasing levels of S. mansoni worm IgG1 to IgG3, S. haematobium worm IgG3, and P. falciparum IgG1 to IgG4.
In the final multivariate model, after age, sex, the TPPA test result, and community were controlled for, independent immunological risk factors for false-positive Murex EIA results were increasing levels of S. mansoni egg IgG1 and S. haematobium worm IgG1 and an RF titer of Ն80 (Table 3 ). In addition, false-positive results were significantly associated with decreasing levels of S. mansoni worm IgG1 and IgG2 and P. falciparum IgG1 and IgG4. 
DISCUSSION
We found that a clinical diagnosis of urinary schistosomiasis was strongly associated with false-positive results by the Murex EIA in a cohort of young people in northwestern Tanzania. Furthermore, among a sample of participants, we observed an extremely strong association between false-positive results and specific immune responses to schistosomiasis, especially increased titers of IgG1 antibody to the S. haematobium worm antigen. We also found a significant independent association between an increased S. mansoni egg IgG1 titer and false- The reasons for these inverse associations are unclear, and any attempt to suggest possible explanations would be purely speculative. Schistosomiasis is endemic in many parts of sub-Saharan Africa and disproportionately affects adolescents. In many areas, most children have been infected by the age of 14 years (27) . In our study population, 73% of the samples had S. haematobium IgG1 OD levels more than 2 standard deviations above the mean for uninfected European controls. A survey of 6,897 schoolchildren aged 7 to 20 years in the Mwanza region of Tanzania found the prevalence of S. haematobium infection to be 56.5% and that of S. mansoni infection to be 10.9% (24) . The schools with the highest S. mansoni prevalence were located less than 5 km from the shore of Lake Victoria, whereas S. haematobium was found in all localities. The wider geographical distribution of S. haematobium is mainly due to the distribution of its intermediate hosts.
We also found a strong association between an RF titer of Ն80 and false-positive Murex EIA results. RF is an autoantibody against the Fc component on IgG and is associated with autoimmune diseases, such as rheumatoid arthritis. However, it can also be produced in individuals with viral, bacterial, and other parasitic infections (30, 34) . It occurs naturally in up to 4% of healthy European populations (20) and in up to 30% of individuals in some ethnic groups (2, 20) . Cross-reactivity between RF and the results of diagnostic tests for malaria has been reported (17, 21) . Cross-reactivity between HIV-1 peptides and antibody to S. mansoni has been demonstrated in sera from children from Kenya infected with S. mansoni and confirmed to be HIV negative (23) Given the high prevalence of schistosomiasis in many African populations and the strong association between S. haematobium IgG1 antibody and false-positive Murex EIA results that we found in our study, a high proportion of falsepositive Murex EIA results and, perhaps, other HIV assays in similar settings in sub-Saharan Africa may be attributable to cross-reactivity with schistosoma antibody. This warrants further investigation.
Our study was a detailed investigation of the possible mechanisms for false positivity following the low specificity that we observed with the Murex EIA in this population. We had chosen this EIA for use as the confirmatory test in a serial testing strategy (13) . While the rate of false-positive results gave considerable cause for concern, we do not believe that this problem is restricted to the Murex EIA. Lower-than-expected specificities were also observed in this study population with other 4th-generation EIAs (unpublished data), including the screening test used in our algorithm, the Uni-Form II Ag/Ab EIA (bioMérieux, Marcy l'Etoile, France), although not to the same degree. Problems of low specificity with HIV EIAs have also been reported elsewhere (8, 22, 32) , and more recently, problems with false positive results by simple rapid point-of-care tests for HIV have been found (15) .
While specificity should be improved when tests are used in combination, the high rates of false-positive results associated with the 4th-generation EIAs may lead to a considerable rise in Although the specificity of the 4th-generation Murex EIA was very low for our study population of adolescents and young adults, we have used the same assay to test older adults in the Mwanza region and found its specificity to be within the manufacturer's reported range (12) . The prevalence of HIV infection in these older groups is much higher, generally ranging from 15 to 30%, whereas it was Ͻ1% in the younger cohort evaluated in the present study. However, although the prevalence of HIV infection will affect the assay's positive predictive value, it should not affect its specificity. The prevalence of schistosomiasis may be lower in older adults, or there may be age-related changes in antibody responses that make crossreactivity less likely (29) . Schistosoma-specific antibody responses in areas where schistosomiasis is endemic have been shown to be dependent on the age of the individual and the intensity of infection (28) . In studies designed to investigate resistance to reinfection with S. mansoni in areas of endemicity after treatment, the levels of IgG2 against parasite egg polysaccharide antigens were found to be the highest in younger children and declined with age, whereas other responses, such as the IgE response against adult worm antigens, tended to rise with age (9, 10).
There are several limitations to our analysis. Due to the colinearity between the immunological tests, it was difficult to disentangle the independent effects of each immunological factor. This was a cross-sectional analysis, and so we cannot determine the causality of the associations observed. Although we did a comprehensive range of IgG isotype assays, we did not have data for S. haematobium egg IgG and did not look at other antibody responses, such as IgA and IgE responses. Lastly, we examined the association of 18 immunological variables with false-positive Murex EIA results, and such multiple statistical testing can produce spurious results. However, a large proportion of the immunological factors were strongly associated with false-positive results, suggesting that this was not a chance finding. If we apply a Bonferroni correction for multiple comparisons, eight of the univariate associations are still statistically significant (P Ͻ 0.0028).
Although the association with schistosomiasis IgG antibody and the RF titer is unlikely to provide the complete picture, it is clear that in our study population of Tanzanian adolescents with a low prevalence of HIV infection, the 4th-generation Murex EIA performed poorly (13) . The p24 antigen component of the 4th-generation tests may partially explain this (22) . The differences in serological response between African populations and those in other regions and the prevalence of parasitological coinfection and the subsequent immune response will affect the performance of HIV assays. Clearly, the best method for resolution of problems of low specificity would be for manufacturers to design and evaluate tests specific for the African environment.
In summary, among adolescents and young adults in northwestern Tanzania, we found a high prevalence of false-positive results by the 4th-generation Murex EIA. Individuals with high levels of IgG1 antibody to S. haematobium soluble worm and S. mansoni soluble egg antigens and an RF titer Ն80 were more likely to have false-positive Murex EIA results. Further research on the cross-reactivity of HIV diagnostic tests with endemic infections in sub-Saharan Africa is warranted.
